top of page

Sustainable Production of Defined Culture-Media Components

Serum-free and chemically defined culture systems provide opportunities to incorporate environmental sustainability into medium design and supply-chain development. Defined composition enables independent evaluation of ingredient origin, manufacturing route, resource requirements, and environmental impact and facilitates the introduction of renewable feedstocks, animal-free manufacturing systems, efficient bioprocesses, and circular-resource strategies. Culture-media constituents broadly comprise low-molecular-weight components, such as amino acids, vitamins, metabolic substrates, inorganic salts, and trace elements, together with macromolecular components including recombinant growth factors, cytokines, albumin, and other carrier proteins. This modular composition enables sustainability assessment at the level of individual ingredients rather than reliance on complex biological mixtures. Microbial fermentation and metabolic engineering provide potential manufacturing routes for low-molecular-weight components, particularly amino acids, and may incorporate renewable or residual biomass as carbon and nutrient sources [Gao et al., 2025; Kim et al., 2024]. Microbial cell-factory engineering can improve substrate conversion, titer, yield, and productivity while enabling alternative feedstock utilization. Environmental performance depends on the complete production chain rather than feedstock origin alone. Feedstock pretreatment, fermentation efficiency, energy and water consumption, downstream purification, waste generation, transportation, and final product quality determine the overall environmental profile. Life-cycle assessment and related quantitative metrics provide suitable approaches for comparing alternative manufacturing routes. Recombinant biotechnology similarly provides controllable and potentially animal-free manufacturing platforms for macromolecular components. Microbial expression systems support production of bioactive FGF2, IGF1, PDGF-BB, and TGF-β1 [Venkatesan et al., 2022]. Optimization of expression hosts, fermentation conditions, protein stability, and downstream purification further improve resource efficiency. Alternative manufacturing routes must simultaneously satisfy purity, biological activity, consistency, and quality requirements to ensure reproducible maintenance of the intended cellular phenotype and function. Integration of chemically defined formulations, recombinant biotechnology, metabolic engineering, renewable feedstocks, and quantitative environmental assessment provides a framework for culture-media development combining biological performance, reproducibility, scalability, process control, and environmental sustainability. Such strategies may progressively reduce dependence on animal-derived resources and support more circular approaches to stem-cell biomanufacturing.

Introduction to Stem Cell Biology and Classification

Stem cells (SCs) represent a fundamental component of developmental biology, tissue homeostasis, and regenerative medicine because of two defining biological properties: self-renewal, referring to the capacity to undergo cell division while maintaining stem-cell identity, as well as differentiation potential, describing the capacity to generate one or more specialized cellular lineages in response to appropriate signals [ISSCR, 2025]. The extent of highlighted properties varies according to developmental origin, tissue context, together with cellular potency. Pluripotent stem cells (PSCs) undergo extensive proliferation while retaining the capacity to generate derivatives of the three embryonic germ layers, namely ectoderm, mesoderm, and endoderm, whereas tissue-specific stem cells generally display a more restricted differentiation repertoire and predominantly contribute to homeostasis and regeneration within their tissue of origin [ISSCR, 2025; Thomson et al., 1998]. Developmental origin and differentiation potential provide complementary criteria for stem-cell classification. According to developmental potency, stem and progenitor populations can be classified as totipotent, pluripotent, multipotent, oligopotent, or unipotent. Totipotency represents the broadest developmental potential and characterizes the zygote and early blastomeres capable of generating both embryonic and extraembryonic tissues. PSCs generate derivatives of all three embryonic germ layers but, under standard definitions, cannot independently generate an entire organism. Multipotent stem cells generate multiple differentiated cell types generally restricted to a defined tissue, organ, or developmental lineage, whereas oligopotent and unipotent progenitors exhibit progressively narrower differentiation capacities. The principal PSC populations used in biomedical research comprise embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs). Human ESCs originate from the inner cell mass of preimplantation blastocysts and exhibit extensive self-renewal and pluripotent differentiation capacity [Thomson et al., 1998].

The establishment of stable human ESC lines provided a renewable experimental platform for investigating early human development, lineage specification, disease mechanisms, and regenerative strategies. Induced pluripotent stem-cell technology subsequently demonstrated that differentiated somatic cells can undergo reprogramming toward a pluripotent state. Human iPSCs generated through ectopic expression of defined transcription factors acquire molecular and functional characteristics associated with pluripotency and, similarly to ESCs, can generate derivatives of ectodermal, mesodermal, and endodermal lineages [Takahashi et al., 2007; Ackermann et al., 2015]. Patient- or donor-specific iPSC lines provide versatile platforms for disease modelling, drug screening, developmental studies, in addition to personalized regenerative approaches without requiring an embryonic source. The clinical translation nevertheless requires stringent control of differentiation efficiency, genomic and epigenetic stability, cellular maturation, manufacturing reproducibility, and safety. Either adult or somatic stem cells comprise heterogeneous tissue-resident populations responsible for cellular turnover, homeostasis, and repair throughout postnatal life. Related differentiation capacity generally reflects the physiological requirements of the tissue in which they reside [ISSCR, 2025]. The surrounding stem-cell niche regulates highlighted functions through cellular interactions, extracellular-matrix components, soluble mediators, metabolic signals, and mechanical cues that influence quiescence, self-renewal, proliferation, and differentiation. Hematopoietic stem cells (HSCs) represent one of the best-characterized multipotent adult stem-cell populations. The long-term self-renewal and capacity to generate all mature blood-cell lineages form the biological basis of hematopoietic stem-cell transplantation [Kim et al., 2014]. HSC research has also established fundamental concepts concerning stem-cell hierarchy, lineage commitment, niche regulation, and the balance between self-renewal and differentiation. Mesenchymal stromal cells (MSCs), historically referred to as mesenchymal stem cells, represent another extensively investigated adult stromal population. Several tissues provide MSCs, including bone marrow, adipose tissue, umbilical cord, and other perinatal tissues. Conventionally defined MSC populations exhibit plastic adherence, characteristic surface-marker profiles, and in vitro osteogenic, adipogenic, and chondrogenic differentiation. The designation “mesenchymal stromal cells” more accurately describes heterogeneous culture-expanded populations for which long-term self-renewal and multipotency at the single-cell level have not been conclusively established [Viswanathan et al., 2019]. MSC biological activity extends beyond differentiation. Paracrine and intercellular signaling mediated by cytokines, chemokines, growth factors, extracellular-matrix regulators, and extracellular vesicles contributes to modulation of inflammatory responses, immune-cell activity, angiogenesis, cell survival, and endogenous tissue repair. All presented properties expanded the role of MSCs from potential cellular building blocks to biologically active signaling platforms and sources of cell-derived therapeutic products.

Stem Cell Isolation and Characterization

Mesenchymal Stromal Cell Sources and Isolation

MSCs can be isolated and culture-expanded from numerous adult and perinatal tissues. Bone marrow, adipose tissue, umbilical cord and Wharton’s jelly, placenta, and dental tissues constitute some of the most extensively investigated sources [Viswanathan et al., 2019; Mattei et al., 2025]. Populations originating from different anatomical compartments fulfil conventional MSC-defining criteria while retaining distinct proliferative, differentiation, secretory, immunomodulatory, transcriptomic, and epigenetic features [Mattei et al., 2025; Lee et al., 2026]. Donor characteristics, tissue procurement, isolation methodology, culture conditions, passage number, and manufacturing strategy introduce additional sources of biological variability. Bone marrow-derived mesenchymal stromal cells (BM-MSCs) historically represent the reference population for comparison with MSCs obtained from alternative tissues. Bone marrow aspirates contain heterogeneous hematopoietic, endothelial, stromal, and progenitor populations, with MSCs representing a relatively small fraction of total nucleated cells. Isolation commonly involves density-gradient separation of the mononuclear fraction followed by culture-based enrichment. Preferential adhesion of stromal cells to tissue-culture plastic, combined with progressive removal of non-adherent hematopoietic cells during medium replacement, generates increasingly enriched MSC cultures. The invasiveness of bone marrow collection, low initial MSC frequency, and donor-associated effects on cellular yield and proliferative capacity have encouraged investigation of alternative sources. Adipose tissue offers high accessibility, substantial tissue availability, and a comparatively abundant stromal compartment [Bourin et al., 2013; Mattei et al., 2025]. The heterogeneous stromal vascular fraction (SVF) obtained directly from adipose tissue differs fundamentally from subsequently isolated and culture-expanded adipose-derived stromal/stem cells (ASCs). SVF contains stromal and progenitor populations together with endothelial cells, pericytes, leukocytes, and other vascular-associated cells, whereas ASCs represent adherent stromal populations progressively selected during culture expansion [Bourin et al., 2013]. Conventional adipose-tissue processing combines washing, mechanical disruption, and enzymatic digestion of the extracellular matrix, frequently through collagenase-based protocols. Centrifugation following digestion separates mature adipocytes and lipid components from the cellular fraction containing the SVF. Washing and filtration provide a cellular preparation suitable for direct characterization or culture-based ASC expansion. Mechanical processing strategies provide alternative approaches to obtain stromal-cell-containing preparations without conventional enzymatic digestion. Processing methodology affects cellular yield, viability, population composition, tissue architecture, and biological properties; consequently, enzymatically isolated SVF, mechanically processed preparations, and culture-expanded ASCs constitute distinct biological preparations requiring method-specific characterization [Bourin et al., 2013; Mattei et al., 2025]. Perinatal tissues, particularly umbilical cord, Wharton’s jelly, and placenta, provide developmentally young stromal populations without requiring an additional invasive procedure for the donor. These populations frequently exhibit robust proliferative capacity and limited replicative ageing compared with several adult tissue-derived populations [Mattei et al., 2025; Lee et al., 2026]. Enzymatic digestion and explant culture represent the principal isolation strategies. Enzymatic approaches disrupt extracellular-matrix components to release individual cells or cellular aggregates, whereas explant methods rely on cellular migration from tissue fragments onto the culture substrate. Isolation methodology can influence the resulting cellular phenotype and molecular profile. Comparative transcriptomic analyses of umbilical cord-derived MSCs have identified differences between enzymatically isolated populations and cells obtained through the Minimal Cube Explant approach, with the latter displaying relative transcriptomic stability across passages [Lee et al., 2026]. Such observations support the influence of processing methodology on subsequent cellular characteristics without establishing universal superiority of a specific isolation strategy.

Current Stem-Cell Platforms and Major Applications

Stem-cell applications depend on the biological properties, differentiation potential, manufacturing requirements, and translational profile of each cellular platform. HSCs represent the most established therapeutic platform and support hematopoietic stem-cell transplantation for malignant and non-malignant hematological disorders [Aljagthmi and Abdel-Aziz, 2025]. MSCs represent an extensively investigated platform for regenerative and immunomodulatory applications. Their activity encompasses differentiation capacity and paracrine mechanisms mediated by cytokines, growth factors, extracellular vesicles, and other bioactive mediators. Clinical outcomes depend on indication, tissue source, manufacturing process, administration strategy, and proposed mechanism of action [Lu and Allickson, 2025]. PSCs, particularly iPSCs, provide central platforms for disease modelling, developmental biology, drug discovery, toxicological assessment, and generation of specialized cells for replacement strategies [Takahashi, 2025; Kirkeby et al., 2025]. Proliferative and differentiation capacities provide substantial advantages but require rigorous control of lineage specification, identity, genomic stability, purity, and residual undifferentiated cells. Cellular agriculture extends stem- and progenitor-cell applications beyond conventional biomedicine. Muscle satellite cells and myoblast progeny provide major myogenic sources for cultivated meat, while MSCs, adipose-derived progenitors, and fibro-adipogenic progenitors support investigation of adipose and connective-tissue components. PSCs provide extensive proliferative potential but require more complex control of lineage-specific differentiation [Olenic et al., 2025; Muller and Matsusaki, 2026]. All highlighted platforms require robust, reproducible, scalable, and increasingly defined culture systems capable of supporting expansion while maintaining application-specific biological properties.

MSC Expansion and Characterization

In vitro expansion provides the cellular quantities required for experimental characterization, manufacturing, and potential therapeutic applications but simultaneously introduces biological selection pressures. Seeding density, basal medium composition, supplementation, oxygen concentration, substrate properties, passage number, and culture duration influence MSC phenotype and functionality. Repeated passages can modify proliferation, morphology, transcriptional programs, differentiation capacity, and secretory activity, while prolonged expansion promotes replicative senescence. Tissue procurement, isolation, expansion, cryopreservation, thawing, and final formulation therefore constitute interconnected variables affecting final product characteristics [Mattei et al., 2025; Renesme et al., 2025]. The minimal criteria established by the International Society for Cell & Gene Therapy (ISCT) provide the conventional framework for culture-expanded MSC characterization. These criteria comprise adherence to plastic under standard culture conditions, expression of CD73, CD90, and CD105, minimal or absent expression of CD45, CD34, CD14 or CD11b, CD79α or CD19, and HLA-DR, together with in vitro osteogenic, adipogenic, and chondrogenic differentiation [Dominici et al., 2006]. Multiparametric flow cytometry enables quantitative assessment of the characteristic immunophenotype and cellular composition. All minimal criteria support standardization and comparison among MSC preparations but do not independently demonstrate stemness, biological equivalence, or therapeutic potency [Viswanathan et al., 2019; Renesme et al., 2025]. Extended characterization may incorporate colony-forming unit-fibroblast assays, proliferation kinetics, population-doubling analysis, senescence assessment, genomic stability, transcriptomics, proteomics, secretome profiling, immunomodulatory activity, angiogenic function, and other application-specific endpoints [Mattei et al., 2025; Renesme et al., 2025].

Functional characterization gains particular relevance in translational applications because many MSC-associated effects depend on paracrine signaling rather than direct differentiation and durable engraftment. Potency assays should therefore reflect the proposed mechanism of action and intended therapeutic function. Immunomodulatory, angiogenic, skeletal, vascular, or soft-tissue applications may consequently require different functional endpoints. A source-, process-, and application-specific framework integrates cellular identity, purity and quality, biological fitness, and functional potency. This approach connects tissue origin and manufacturing conditions with critical quality attributes and intended biological activity, thereby providing a more comprehensive basis for translational development than conventional phenotypic criteria alone.

Hematopoietic Stem Cell Isolation and Characterization

HSCs sustain lifelong hematopoiesis through self-renewal and multilineage differentiation. Hematopoietic stem and progenitor cells (HSPCs) used in research and clinical transplantation derive primarily from bone marrow, mobilized peripheral blood, and umbilical cord blood [Broxmeyer et al., 1989]. Bone marrow aspiration provides marrow-derived HSPCs, while pharmacological mobilization enables migration of HSPCs into peripheral circulation for collection by leukapheresis. Umbilical cord blood collected after delivery provides an additional clinically relevant source. Density-gradient centrifugation separates the mononuclear cell fraction, while immunomagnetic selection or fluorescence-activated cell sorting enables subsequent enrichment according to surface-antigen expression. CD34 represents the principal marker used for human HSPC identification and enrichment, although the CD34⁺ compartment contains primitive HSCs together with lineage-committed progenitors [Civin et al., 1984]. Multiparametric combinations incorporating CD38, CD90, CD45RA, and CD49f provide greater resolution and enrichment of primitive populations displaying long-term repopulating potential [Notta et al., 2011]. Immunophenotypic characterization is further complemented by functional assays capable of evaluating the biological properties of the isolated cells. Colony-forming unit assays quantify clonogenic and lineage potential, whereas long-term culture-initiating cell assays identify primitive populations capable of sustained progenitor generation in vitro [Sutherland et al., 1990]. Long-term multilineage hematopoietic reconstitution following transplantation remains the most stringent experimental demonstration of HSC function [Notta et al., 2011].

Pluripotent Stem Cell Derivation and Characterization

iPSCs originate from differentiated somatic cells reprogrammed through activation of transcriptional and epigenetic networks associated with pluripotency. Fibroblasts initially represented the predominant cellular source, although numerous somatic populations, including peripheral blood-derived cells, now support iPSC generation [Takahashi and Yamanaka, 2006; Takahashi et al., 2007; Yu et al., 2007]. Takahashi and Yamanaka first demonstrated reprogramming of mouse fibroblasts through Oct3/4 (POU5F1), Sox2, Klf4, and c-Myc [Takahashi and Yamanaka, 2006]. Subsequent application of OCT4, SOX2, KLF4, and c-MYC generated human iPSCs from adult fibroblasts [Takahashi et al., 2007], while an independent approach employed OCT4, SOX2, NANOG, and LIN28 [Yu et al., 2007]. Initial reprogramming systems relied predominantly on integrating viral vectors. Concerns regarding insertional mutagenesis, persistent transgene expression, and genomic integrity stimulated the development of integration-free approaches based on non-integrating viral vectors, episomal DNA, and synthetic modified mRNA [Yu et al., 2009; Warren et al., 2010]. More recent small-molecule-based strategies modulate endogenous transcriptional, signaling, metabolic, and epigenetic pathways without conventional transcription-factor delivery [Peng et al., 2025]. Characterization of candidate iPSC lines includes analysis of core pluripotency-associated factors such as OCT4, SOX2, and NANOG, evaluation of pluripotency-associated surface markers, and demonstration of differentiation toward ectodermal, mesodermal, and endodermal derivatives [Takahashi et al., 2007; Yu et al., 2007]. Genomic integrity, stability during expansion, and absence of residual reprogramming vectors or transgenes constitute additional quality parameters for disease modelling, drug discovery, developmental studies, and translational applications [Yu et al., 2009; Warren et al., 2010].

Stem Cell Maintenance and Culture Media Optimization

Culture Media Composition and Serum Requirements

The culture microenvironment strongly regulates stem-cell identity, expansion, and function. Culture media provide metabolic substrates, ions, vitamins, growth factors, cytokines, hormones, and signaling molecules that influence proliferation, survival, self-renewal, differentiation, and metabolism. Medium composition consequently affects biological properties and reproducibility, particularly during prolonged or large-scale expansion [Gottipamula et al., 2013; Cimino et al., 2017]. Distinct requirements among MSCs, HSCs, and PSCs necessitate cell- and application-specific culture conditions. Fetal bovine serum (FBS) has traditionally supported MSC expansion by providing growth factors, hormones, attachment-promoting molecules, carrier proteins, and additional biological components [Gottipamula et al., 2013; Cimino et al., 2017]. The incompletely defined composition, lot-to-lot variability, and xenogeneic origin nevertheless limit reproducibility and introduce potential concerns related to adventitious agents and immune sensitization [Cimino et al., 2017; Guiotto et al., 2020]. Human platelet lysate, serum-free formulations, xeno-free systems, and chemically defined media provide alternative strategies [Guiotto et al., 2020]. Serum-free formulations exclude serum but retain human- or animal-derived biological components. Xeno-free systems exclude non-human animal-derived materials, whereas chemically defined formulations contain components of specified identity and concentration. Increasingly defined systems enhance reproducibility, traceability, standardization, and process control when they preserve required biological attributes. Selected serum-free formulations supported sustained proliferation, reduced senescence, favorable immunological characteristics, and genomic stability in adipose-derived MSCs [Lee et al., 2022], while xeno- and serum-free conditions have supported long-term expansion of umbilical cord-derived MSCs [Le et al., 2021]. Different serum-free formulations nevertheless produce distinct effects on proliferation, senescence, cell-cycle distribution, and paracrine activity despite comparable morphology and conventional surface-marker profiles [Lee et al., 2022; Zhao et al., 2024]. Defined culture environments also support other stem-cell populations. Feeder-free chemically defined systems such as E8 enable long-term human PSC expansion while maintaining pluripotency [Chen et al., 2011]. Serum-free and chemically defined HSC culture systems provide increasingly precise control of survival, self-renewal, and differentiation and have enabled substantial ex vivo expansion of functional human HSC populations [Sakurai et al., 2023].

Culture-Media Components and Functional Optimization

Basal media contain low-molecular-weight nutrients and physicochemical components, including glucose and other metabolic substrates, amino acids, inorganic salts, vitamins, trace elements, and buffering systems. Cell-specific formulations additionally contain lipids, hormones, carrier proteins, recombinant growth factors, cytokines, extracellular-matrix-associated components, and small-molecule signaling modulators [Chen et al., 2011; Kuo et al., 2020]. Concentration, combination, stability, and bioavailability of individual components regulate cellular metabolism, proliferation, survival, self-renewal, differentiation, and functional activity. Medium optimization therefore requires predefined quality and functional attributes rather than proliferation rate alone. Relevant parameters include expansion capacity, maintenance of stem-cell-associated properties, differentiation competence, genomic stability, secretory activity, and application-specific potency. Chemically defined formulations facilitate process development because individual ingredients can be independently quantified, optimized, or replaced. The E8 system established a simplified chemically defined environment for PSC culture [Chen et al., 2011], while the subsequent B8 formulation demonstrated the potential for rational medium design and recombinant growth-factor production to reduce culture costs [Kuo et al., 2020]. Recombinant platforms can produce biologically relevant factors including FGF2, IGF1, PDGF-BB, and TGF-β1 [Venkatesan et al., 2022], while emerging synthetic molecules may eventually replace selected protein components or reproduce specific signaling activities [Feofanov et al., 2025].

References

  • Ackermann, M., Liebhaber, S., Klusmann, J. H., & Lachmann, N. (2015). Lost in translation: Pluripotent stem cell-derived hematopoiesis. EMBO Mol. Med., 7(11), 1388-1402. https://doi.org/10.15252/emmm.201505301

  • Aljagthmi, A. A., & Abdel-Aziz, A. K. (2025). Hematopoietic stem cells: Understanding the mechanisms to unleash the therapeutic potential of hematopoietic stem cell transplantation. Stem Cell Res. Ther., 16(1), 60. https://doi.org/10.1186/s13287-024-04126-z

  • Bourin, P., Bunnell, B. A., Casteilla, L., Dominici, M., Katz, A. J., March, K. L., Redl, H., Rubin, J. P., Yoshimura, K., & Gimble, J. M. (2013). Stromal cells from the adipose tissue-derived stromal vascular fraction and culture expanded adipose tissue-derived stromal/stem cells: A joint statement of the International Federation for Adipose Therapeutics and Science (IFATS) and the International Society for Cellular Therapy (ISCT). Cytotherapy, 15(6), 641-648. https://doi.org/10.1016/j.jcyt.2013.02.006

  • Broxmeyer, H. E., Douglas, G. W., Hangoc, G., Cooper, S., Bard, J., English, D., Arny, M., Thomas, L., & Boyse, E. A. (1989). Human umbilical cord blood as a potential source of transplantable hematopoietic stem/progenitor cells. Proc. Natl. Acad. Sci. U.S.A., 86(10), 3828-3832. https://doi.org/10.1073/pnas.86.10.3828

  • Chen, G., Gulbranson, D. R., Hou, Z., Bolin, J. M., Ruotti, V., Smuga-Otto, K., Howden, S. E., Diol, N. R., Propson, N. E., Wagner, R., Lee, G. O., Antosiewicz-Bourget, J., Teng, J. M. C., & Thomson, J. A. (2011). Chemically defined conditions for human iPSC derivation and culture. Nat. Methods, 8(5), 424-429. https://doi.org/10.1038/nmeth.1593

  • Cimino, M., Gonçalves, R. M., Barrias, C. C., & Martins, M. C. L. (2017). Xeno-Free Strategies for Safe Human Mesenchymal Stem/Stromal Cell Expansion: Supplements and Coatings. Stem Cells Int., 2017, 6597815, 1-13. https://doi.org/10.1155/2017/6597815

  • Civin, C. I., Strauss, L. C., Brovall, C., Fackler, M. J., Schwartz, J. F., & Shaper, J. H. (1984). Antigenic analysis of hematopoiesis. III. A hematopoietic progenitor cell surface antigen defined by a monoclonal antibody raised against KG-1a cells. J. Immunol., 133(1), 157-165. https://doi.org/10.4049/jimmunol.133.1.157

  • Dominici, M., Le Blanc, K., Mueller, I., Slaper-Cortenbach, I., Marini, F. C., Krause, D. S., Deans, R. J., Keating, A., Prockop, D. J., & Horwitz, E. M. (2006). Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy, 8(4), 315-317. https://doi.org/10.1080/14653240600855905

  • Feofanov, M., Daubner, G. M., Saltalamacchia, A., Köhler, K., Schulz, C., Henry, C. E., Ziegler, M. J., Benabderrahmane, M., Hiault, F. A., Decker, T. M., Shen, M. C., Pahl, J., Lambertz, S., & Noori, H. R. (2025). Discovery and optimization of a guanylhydrazone-based small molecule to replace bFGF for cell culture applications. Biochem. Biophys. Rep., 43, 102167. https://doi.org/10.1016/j.bbrep.2025.102167

  • Gao, Y., Liu, A., Zhang, X., Zhang, W., Wang, X., Xu, G., Zhang, X., Li, H., Shi, J., & Xu, Z. (2025). Enhanced L-serine production in Corynebacterium glutamicum via promoter engineering and Bayesian optimization. World J. Microbiol. Biotechnol., 41(7), 216. https://doi.org/10.1007/s11274-025-04401-y

  • Gottipamula, S., Muttigi, M. S., Kolkundkar, U., & Seetharam, R. N. (2013). Serum-free media for the production of human mesenchymal stromal cells: A review. Cell Prolif., 46(6), 608-627. https://doi.org/10.1111/cpr.12063

  • Guiotto, M., Raffoul, W., Hart, A. M., Riehle, M. O., & Di Summa, P. G. (2020). Human platelet lysate to substitute fetal bovine serum in hMSC expansion for translational applications: A systematic review. J. Transl. Med., 18(1), 351. https://doi.org/10.1186/s12967-020-02489-4

  • International Society for Stem Cell Research (ISSCR). (2025). Guidelines for Stem Cell Research and Clinical Translation (Version 1.2). ISSCR.

  • Kim, A. D., Stachura, D. L., & Traver, D. (2014). Cell signaling pathways involved in hematopoietic stem cell specification. Exp. Cell Res., 329(2), 227-233. https://doi.org/10.1016/j.yexcr.2014.10.011

  • Kim, M., Oh, J. W., Jeong, D. W., Cho, B. H., Chang, J., Shi, X., & Han, S. O. (2024). Biosynthesis of L-histidine from marine biomass-derived galactans in metabolically engineered Corynebacterium glutamicum. Bioresour. Technol., 391(Pt. A), 129963. https://doi.org/10.1016/j.biortech.2023.129963

  • Kirkeby, A., Main, H., & Carpenter, M. (2025). Pluripotent stem-cell-derived therapies in clinical trial: A 2025 update. Cell Stem Cell, 32(1), 10-37. https://doi.org/10.1016/j.stem.2024.12.005

  • Kuo, H. H., Gao, X., DeKeyser, J. M., Fetterman, K. A., Pinheiro, E. A., Weddle, C. J., Fonoudi, H., Orman, M. V., Romero-Tejeda, M., Jouni, M., Blancard, M., Magdy, T., Epting, C. L., George, A. L., & Burridge, P. W. (2020). Negligible-Cost and Weekend-Free Chemically Defined Human iPSC Culture. Stem Cell Rep., 14(2), 256-270. https://doi.org/10.1016/j.stemcr.2019.12.007

  • Le, H. M., Nguyen, L. T., Hoang, D. H., Bach, T. Q., Nguyen, H. T. N., Mai, H. T., Trinh, D. P., Nguyen, T. D., Nguyen, L. T., & Than, U. T. T. (2021). Differential development of umbilical cord-derived mesenchymal stem cells during long-term maintenance in fetal bovine serum-supplemented medium and xeno- and serum-free culture medium. Cell Reprogram., 23(6), 359-369. https://doi.org/10.1089/cell.2021.0050

  • Lee, J. Y., Kang, M. H., Jang, J. E., Lee, J. E., Yang, Y., Choi, J. Y., Kang, H. S., Lee, U., Choung, J. W., Jung, H., Yoon, Y. C., Jung, K. H., Hong, S. S., Yi, E. C., & Park, S. G. (2022). Comparative analysis of mesenchymal stem cells cultivated in serum free media. Sci. Rep., 12(1), 8620. https://doi.org/10.1038/s41598-022-12467-z

  • Lee, M. J., Park, K., Won, S., & Jo, C. H. (2026). Comparative transcriptomic profiling of mesenchymal stem cells from distinct tissue origins and isolation methods highlights the stability and immunomodulatory signature of umbilical cord-derived Smumf cells. Tissue Eng. Regen. Med., 23(1), 157-173. https://doi.org/10.1007/s13770-025-00765-2

  • Lu, W., & Allickson, J. (2025). Mesenchymal stromal cell therapy: Progress to date and future outlook. Mol. Ther., 33(6), 2679-2688. https://doi.org/10.1016/j.ymthe.2025.02.003

  • Mattei, V., Santilli, F., Pulcini, F., Fabrizi, J., Lancia, L., Santacroce, C., Megiorni, F., Ceccarelli, S., Paldino, E., Gramignoli, R., Roubelakis, M. G., Bahareh, S., Vosough, M., Bollini, S., Galderisi, U., Salgado, A. J., Angeloni, A., Marchese, C., & Delle Monache, S. (2025). Validated methods for isolation and qualification of mesenchymal stromal/stem cells from different sources. J. Transl. Med., 23, 975. https://doi.org/10.1186/s12967-025-06972-8

  • Muller, Q., & Matsusaki, M. (2026). Comparative analysis of cultivated meat cell sources and cell type usage across species: Functional roles and engineering potential. Trends Food Sci. Technol., 169, 105524. https://doi.org/10.1016/j.tifs.2025.105524

  • Notta, F., Doulatov, S., Laurenti, E., Poeppl, A., Jurisica, I., & Dick, J. E. (2011). Isolation of single human hematopoietic stem cells capable of long-term multilineage engraftment. Science, 333(6039), 218-221. https://doi.org/10.1126/science.1201219

  • Olenic, M., Deelkens, C., Heyman, E., De Vlieghere, E., Zheng, X., Van Hengel, J., De Schauwer, C., Devriendt, B., De Smet, S., & Thorrez, L. (2025). Review: Livestock cell types with myogenic differentiation potential: Considerations for the development of cultured meat. Animal, 19(Suppl. 1), 101242. https://doi.org/10.1016/j.animal.2024.101242

  • Peng, F., Wang, Y., Cheng, L., Cai, R., Fu, X., Yang, Z., Cheng, R., Zeng, W., Dong, Y., Cao, J., Mao, J., Zeng, J., Liu, T., Chen, G., Lei, Q., Wang, L., Liu, L., Sun, S., Li, C., Mu, R., Guan, J., & Deng, H. (2025). Chemical reprogramming of human blood cells to pluripotent stem cells. Cell Stem Cell, 32(8), 1192-1199.e11. https://doi.org/10.1016/j.stem.2025.07.003

  • Renesme, L., Cobey, K. D., Lalu, M. M., Bubela, T., Chinnadurai, R., De Vos, J., Dunbar, R., Fergusson, D., Freund, D., Galipeau, J., Horwitz, E., Lê, M., Matthay, M., Moher, D., Nolta, J., Parker, G., Phinney, D. G., Rao, M., Rasko, J. E. J., et al. (2025). Delphi-driven consensus definition for mesenchymal stromal cells and clinical reporting guidelines for mesenchymal stromal cell-based therapeutics. Cytotherapy, 27(2), 146-168. https://doi.org/10.1016/j.jcyt.2024.10.008

  • Sakurai, M., Ishitsuka, K., Ito, R., Wilkinson, A. C., Kimura, T., Mizutani, E., Nishikii, H., Sudo, K., Becker, H. J., Takemoto, H., Sano, T., Kataoka, K., Takahashi, S., Nakamura, Y., Kent, D. G., Iwama, A., Chiba, S., Okamoto, S., Nakauchi, H., & Yamazaki, S. (2023). Chemically defined cytokine-free expansion of human haematopoietic stem cells. Nature, 615(7950), 127-133. https://doi.org/10.1038/s41586-023-05739-9

  • Sutherland, H. J., Lansdorp, P. M., Henkelman, D. H., Eaves, A. C., & Eaves, C. J. (1990). Functional characterization of individual human hematopoietic stem cells cultured at limiting dilution on supportive marrow stromal layers. Proc. Natl. Acad. Sci. U.S.A., 87(9), 3584-3588. https://doi.org/10.1073/pnas.87.9.3584

  • Takahashi, K., & Yamanaka, S. (2006). Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell, 126(4), 663-676. https://doi.org/10.1016/j.cell.2006.07.024

  • Takahashi, K., Tanabe, K., Ohnuki, M., Narita, M., Ichisaka, T., Tomoda, K., & Yamanaka, S. (2007). Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell, 131(5), 861-872. https://doi.org/10.1016/j.cell.2007.11.019

  • Takahashi, J. (2025). iPSC-based cell replacement therapy: From basic research to clinical application. Cytotherapy, 27(7), 835-842. https://doi.org/10.1016/j.jcyt.2025.01.015

  • Thomson, J. A., Itskovitz-Eldor, J., Shapiro, S. S., Waknitz, M. A., Swiergiel, J. J., Marshall, V. S., & Jones, J. M. (1998). Embryonic stem cell lines derived from human blastocysts. Science, 282(5391), 1145-1147. https://doi.org/10.1126/science.282.5391.1145

  • Venkatesan, M., Semper, C., Skrivergaard, S., Di Leo, R., Mesa, N., Rasmussen, M. K., Young, J. F., Therkildsen, M., Stogios, P. J., & Savchenko, A. (2022). Recombinant production of growth factors for application in cell culture. iScience, 25(10), 105054. https://doi.org/10.1016/j.isci.2022.105054

  • Viswanathan, S., Shi, Y., Galipeau, J., Krampera, M., Le Blanc, K., Martin, I., Nolta, J., Phinney, D. G., & Sensebé, L. (2019). Mesenchymal stem versus stromal cells: International Society for Cell & Gene Therapy (ISCT®) Mesenchymal Stromal Cell committee position statement on nomenclature. Cytotherapy, 21(10), 1019-1024. https://doi.org/10.1016/j.jcyt.2019.08.002

  • Warren, L., Manos, P. D., Ahfeldt, T., Loh, Y. H., Li, H., Lau, F., Ebina, W., Mandal, P. K., Smith, Z. D., Meissner, A., Daley, G. Q., Brack, A. S., Collins, J. J., Cowan, C., Schlaeger, T. M., & Rossi, D. J. (2010). Highly efficient reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA. Cell Stem Cell, 7(5), 618-630. https://doi.org/10.1016/j.stem.2010.08.012

  • Yu, J., Vodyanik, M. A., Smuga-Otto, K., Antosiewicz-Bourget, J., Frane, J. L., Tian, S., Nie, J., Jonsdottir, G. A., Ruotti, V., Stewart, R., Slukvin, I. I., & Thomson, J. A. (2007). Induced pluripotent stem cell lines derived from human somatic cells. Science, 318(5858), 1917-1920. https://doi.org/10.1126/science.1151526

  • Yu, J., Hu, K., Smuga-Otto, K., Tian, S., Stewart, R., Slukvin, I. I., & Thomson, J. A. (2009). Human induced pluripotent stem cells free of vector and transgene sequences. Science, 324(5928), 797-801. https://doi.org/10.1126/science.1172482

  • Zhao, L., Ni, B., Li, J., Liu, R., Zhang, Q., Zheng, Z., Yang, W., Yu, W., & Bi, L. (2024). Evaluation of the impact of customized serum-free culture medium on the production of clinical-grade human umbilical cord mesenchymal stem cells: Insights for future clinical applications. Stem Cell Res. Ther., 15(1), 327. https://doi.org/10.1186/s13287-024-03949-0

bottom of page